Re:US weighs Google break-up in landmark antitrust case
by edmundsauto on Wednesday October 09, 2024 @11:14PM
(#41795130)
Right, but in some cases volume doesn’t make up for the price drop. Or the source materials are the bottleneck. Even if the societal benefit was greater.
Re:US weighs Google break-up in landmark antitrust case
by simiones on Thursday October 10, 2024 @08:00AM
(#41797973)
If the drug is needed by 1 million people, selling it for $1 will net you $1 million (let's assume all the 1 million can afford $1). If they instead sell it for $1000 and only 2000 people who need it can afford it, they'll make $2 million, so it's much more economically efficient.
Re:US weighs Google break-up in landmark antitrust case
by consteval on Thursday October 10, 2024 @12:48PM
(#41800743)
No, because once those people take the drug then cash flow disappears, because they're cured. It's ideal to stretch out the adoption of the drug as much as possible in that situation.
It's the same reason SAAS took off so much. If you sell the product and consumers are (relatively) happy, now what? They might come back and buy another version in 5-10 years, but how do you generate enough cash flow between now and then to stay afloat?
Re:US weighs Google break-up in landmark antitrust case
by s1artibartfast on Thursday October 10, 2024 @01:49PM
(#41801350)
Thats not very true for drugs, especially a theoretical cure all.
The time value of money means you want to sell every dose as soon as possible. with a 10% annual return, $1,000 today is better than $2,600 in 10 years.
Additionally, each day that passes, someone else can come in and outperform you or undercut your price.
A rational company would lower the price if that broadened the market and netted more profit by volume. Drugs aren't Veblen goods.
The impetus for jacking up drug prices is that the market is captive, and those who need the drug will obtain it. That and insurance/government is often the payor.